



ALLIANCE
AGAINST
CANCER

5TH ANNUAL MEETING

NEW TECHNOLOGIES AND STRATEGIES TO FIGHT CANCER

OCTOBER 28-30, 2020 - **VIRTUAL MODE**



ORGANIZED BY



IEO
Istituto Europeo di Oncologia



UNIVERSITÀ DEGLI STUDI DI MILANO

COMMITTEES

ALLIANCE AGAINST CANCER

RUGGERO DE MARIA, ROME

PAOLO DE PAOLI, ROME

EXECUTIVE COMMITTEE

GENNARO CILIBERTO, ROME

PIER GIUSEPPE PELICCI, MILAN

ANNA SAPINO, TURIN

HOST INSTITUTIONS

EUROPEAN INSTITUTE OF ONCOLOGY - IEO IRCCS, MILAN

UNIVERSITY OF MILAN

COORDINATOR

ROBERTO ORECCHIA, MILAN

SCIENTIFIC COMMITTEE

GIOVANNI APOLONE, MILAN

GERARDO BOTTI, NAPLES

GENNARO CILIBERTO, ROME

SILVIA FRANCESCHI, AVIANO - PORDENONE

GIOVANNI MARTINELLI, MELDOLA - FORLÌ CESENA

ANGELO PARADISO, BARI

PIER GIUSEPPE PELICCI, MILAN

PAOLO PRONZATO, GENOVA

GIANDOMENICO RUSSO, ROME

ANNA SAPINO, CANDIOLO - TURIN

ORGANIZING COMMITTEE AND PRESS OFFICE

MYRIAM ALCALAY, MILAN

MASSIMO BONI, ROME

CRISTINA BONVICINI, MILAN

EVA BRUSCHINI, MILAN

ENRICO DERENZINI, MILAN

LUCA MAZZARELLA, MILAN

Wednesday

PROGRAM 28-10-2020

08:30-09:00

OPENING SESSION AUTHORITIES

Roberto Orecchia, Scientific Director, IEO IRCCS

Ruggero De Maria, President, Alliance Against Cancer

Maria Pia Abbraccio, Pro-Rector, Milan University

Giovanni Leonardi, General Director of Research and Innovation in Health Innovation, Italian MoH

Mauro Melis, Chief Executive Officer, IEO IRCCS

Giuseppe Sala, Mayor of Milan

09:00- 13:30

SESSION 1: PRE-CLINICAL BREAKTHROUGHS

Intra-tumour heterogeneity; microenvironment; mechanisms of metastasis and drug-resistance; novel therapeutic approaches.

Chairs **Paolo Dellabona**, Director, Division of Immunology, Transplantation and Infectious Diseases and Research, HSR IRCCS

Alberto Mantovani, Scientific Director, Humanitas IRCCS

Gioacchino Natoli, Department of Experimental Oncology, IEO IRCCS

09:00-09:45

Yinyin Yuan, ICR-The Institute of Cancer Research

Deciphering the tumor microenvironment with computational pathology

09:45-10:00

Davide Ceresa, Ospedale Policlinico San Martino, Genova

Liquid biopsy to evaluate triple negative breast cancer heterogeneity: an innovative study using genetic barcoding

10:00-10:15

Elena Magrini, Humanitas IRCCS

Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression

10:15-10:30

Roberta Noberini, IEO IRCCS

Epi-proteomics profiling of clinical samples reveals novel hallmarks of cancer and biomarkers for breast cancer patient stratification

10:30-10:45

Samuele Notarbartolo, INGM

Phenotypic and functional characterization of infiltrating effector T cell heterogeneity in primary and metastatic CRC

10:45-11:00

Mariangela Russo, Candiolo IRCCS

Stress-induced mutagenesis favors adaptation of colorectal cancers in response to targeted therapies

11:00-11:15

Annalisa Tocci, IRE IRCCS

hMENA11a loss activates Type I IFN and inflammatory pathways, and in turn PD-L1 expression, by activating the viral sensor RIG-I

11:30-12:45

Round Table

Current and up-coming technologies to study intra-tumor genetic and phenotypic heterogeneity

Discussants

Andrea Biondi, Director, Department of Pediatric, Fondazione MBBM/Ospedale San Gerardo and University of Milano-Bicocca

Massimiliano Pagani, IFOM and Milan University

Angela Santoni, Scientific Director, Istituto Pasteur Italia-Fond. Cenci Bolognetti

Luca Quagliata, PhD, BCMAS, Vice-President, Global Head of Medical Affairs, Thermo Fisher Scientific

12:45-13:30

Selected Posters

12:45

Fabrizio Antonangeli, CNR c/o Sapienza University of Rome

Gut microbiota alterations affect glioma growth and innate immune cells involved in tumor immunosurveillance

- 12:52** **Natalia Di Ianni**, Besta IRCCS
Radiotherapy treatment in combination with Dendritic Cell Immunotherapy polarizes microglia from M2 to M1 phenotype
- 12:59** **Stefania Faletti**, IEO IRCCS
LSD1 and the adaptive integrated stress response: a novel pathway maintaining tumor initiating cells in human GBM
- 13:06** **Eugenia Giuliani**, Sapienza University
Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response
- 13:13** **Barbara Pasculli**, IRCCS Casa Sollievo della Sofferenza
Clinical association of mir-155-5p with breast cancer and its putative relevance for the treatment with PARP inhibitors
- 13:20** **Giorgia Simonetti**, IRST IRCCS
Metabolomics identifies a subgroup of NPM1-mutant acute myeloid leukemia with genomic and transcriptomic specificities
- 13:30-15:30** **HIGHLIGHT SESSION 1: COVID-19 AND CANCER**
Biology of COVID19 and diverse patient responses; COVID19 and cancer links
- Chairs** **Silvio Brusaferrò**, President, Istituto Superiore di Sanità,
Franco Locatelli, President, Consiglio Superiore della Sanità, Italian MoH
- 13:30-14:15** **Sergio Abrignani**, Scientific director, INGM and University of Milan
Effector and memory lymphocyte responses elicited by Sars-Cov2 infection in man
- 14:15-15:30** **Round Table**
Cancer patient challenges: limited access to cancer screenings and care, worse Covid-19 prognosis
- Discussants** **Giovanni Rezza**, Direttore Generale Prevenzione, Ministero della Salute
Giuseppe Ippolito, Scientific Director, INMI Ospedale Spallanzani

Nicola Silvestris, Giovanni Paolo II IRCCS, Oncologico Bari

Giuseppe Curigliano, IEO IRCCS and University of Milan

Sergio Abrignani, Scientific director, INGM and University of Milan

15:30-20:00

SESSION 2: CANCER PREVENTION AND EARLY-DETECTION

Assessment of Genetic and Environmental cancer-risk factors; Early-diagnosis biomarkers

Chairs **Silvia Franceschi**, Scientific Director, CRO IRCCS

Giuseppe Opocher, Scientific Director, IOV IRCCS

Giuseppe Remuzzi, Scientific Director, Mario Negri Institute for Pharmacological Research IRCCS

15:30-16:15

Annarosa Del Mistro, IOV IRCCS

Towards universal prevention of a tumour: the case of HPV and cervical cancer

16:15-17:00

Maurizio D'Incalci, Mario Negri Institute for Pharmacological Research IRCCS

Early Diagnosis of Ovarian Cancer by the Analysis of TP53 Clonal Variants in cervical cells.

17:00-17:15

Silvia Cascianelli, Politecnico Milano

Boosting perspectives for breast cancer intrinsic subtyping on RNA-sequencing data

17:15-17:30

Mara Colombo, INT IRCCS

BRCA gene splicing analysis identified a large number of pathogenic variants in Italian breast/ovarian cancer families

17:30-17:45

Sara Raimondi, IEO IRCCS

Association of MC1R genotype with melanoma risk according to sun exposure

17:45-18:00

Andrew M. Thomas, CIBIO

Gut microbial signatures for colorectal cancer detection within and across cohorts

18:00-19:15

Round Table

Personal-data sharing, property and privacy

Discussants **Roberto de Miro**, FAVO - Federazione Volontari Italiani
Annarosa Del Mistro, IOV IRCCS
Maurizio D'Incalci, Mario Negri Institute for Pharmacological Research IRCCS
Stefano Ferretti, AIRTUM - Associazione Italiana Registri Tumori
Maurizio Genuardi, Policlinico Gemelli IRCCS
Carlo La Vecchia, Milan University

19:15-20:00

Selected Posters

19:15

Matteo Allegretti, IRE IRCCS

LiqBreasTrack: liquid biopsy in T-DM1- treated HER2+ breast cancer patients

19:23

Tiziana Bonaldi, IEO IRCCS

Identification of biomarkers for lung cancer early diagnosis by MS-based serum proteomics

19:31

Evaristo Cisbani, ISS

Innovative molecular breast imaging device for early cancer diagnosis

19:39

Luigino Dal Maso, CRO IRCCS

Indicators of cancer cure for European patients: Results from the EURO CARE-5 study

19:47

Giuseppa De Luca, S. Martino IRCCS

Going beyond WGA: Optimization of a Molecular Tagging-Based NGS Protocol for CTCs Mutational Profiling

PROGRAM 29-10-2020

thursday

08:30-13:00

SESSION 3: INNOVATIVE TREATMENTS

Genomic-based Clinical Trials, Immunotherapy, Radiotherapy

Chairs **Lisa Licitra**, Scientific Director, CNAO
Giovanni Martinelli, Scientific Director, IRST IRCCS
Giovanni Scambia, Scientific Director, Policlinico Gemelli IRCCS

08:30-09:15

Angelica Facoetti, CNAO

Carbon ion therapy: new insights in the biological mechanisms of tumor control

09:15-10:00

Christophe Le Tourneau, D3i, Institut Curie

Drug development in oncology in the era of precision medicine

10:00-10:15

Silvia Bortolussi, INFN Pavia

Boron Neutron Capture Therapy: an emerging selective form of hadrontherapy as a therapeutic option for disseminated tumours

10:15-10:30

Antonio Camera, OPBG IRCCS

GD2-specific chimeric antigen receptor (CAR) T cells incorporating CD28.4-1BB costimulatory domains for treatment of GD2+ sarcomas

10:30-10:45

Gloria Delfanti, HSR IRCCS

Dual targeting of cancer and suppressive myeloid cells by tumor-redirected iNKT cells and antigen-carrying microparticles

10:45-11:00

Simona Manni, OPBG IRCCS

Strategies to increase CAR T-cell safety and to prevent epitope masking in CAR+ B-cell leukemia blasts

11:00-12:15

Round Table

New treatments: Research Priorities

Discussants

Angelica Facoetti, CNAO

Christophe Le Tourneau, Institut Curie

Corrado Tarella, IEO IRCCS

Giampaolo Tortora, Policlinico Gemelli IRCCS

Clemens Schmitt, MDC Berlin

Pier Luigi Zinzani, Bologna University

12:15-13:00

Selected Posters

12:15

Alfredo Budillon, INT "Pascale", IRCCS

Neoadjuvant nivolumab in early stage colon cancer induces promising tumor regression and T cell infiltration

12:22

Marika Guercio, OPBG IRCCS

CAR T-cell therapy for the treatment of Germ Cell Tumors (GCTs) with heterogeneous tumor antigen expression

12:29

Angela Di Giannatale/Luca Boldrini, OPBG IRCCS

Radiogenomics prediction of MYCN status in neuroblastoma: a hypothesis generating study

12:36

Giuseppe Fanetti, CRO IRCCS

Comorbidities and Cetuximab concomitantly to radiation for platinum- unfit head and neck squamous cell carcinoma patients

12:43

Maria B. Ligabue, Ausl-IRCCS Reggio Emilia

Efficacy of self- administered complex decongestive therapy on breast cancer-related lymphedema: a single- blind randomized controlled trial

12:50

Francesca Paolini/Aldo Venuti, IRE IRCCS

An Old Idea Reinvigorated: Plant-Derived Hpv Chimeric Vaccines For Cancer Treatment.

13:00-13:45

Special Lecture Communicating Cancer Research To the public

Daniela Ovadia, Fondamentale AIRC

Introduced by **Anna Sapino**, Scientific Director, Candiolo IRCCS

13:45-14:30

Special Lecture: Patient involvement and empowerment

Salvo Testa, President, Mutagens Foundation

Introduced by **Francesco de Lorenzo**, President, AIMaC
Gabriella Pravettoni, IEO IRCCS and Milan University

14:30-17:30

HIGHLIGHT SESSION 2: HIGH-DEFINITION ONCOLOGY

National and International Data-sharing infrastructures; Real World Data; Outcomes Research

Chairs **Gennaro Ciliberto**, Scientific Director, IRE IRCCS
Pier Giuseppe Pelicci, IEO and Scientific Coordinator ACC
Fabrizio Tagliavini, Scientific Director, Besta IRCCS

14:30-15:15

David Kerr, Radcliffe Department of Medicine, University of Oxford

International collaboration to collect real time anti cancer drug delivery data

15:15-15:35

Letizia Tanca, Politecnico Milano

The Health Big Data Project: Challenges and Approaches

15:35-15:55

Piers Mahon, Senior Principal and European Leader, Oncology Evidence Networks at IQVIA

DIGICORE: an international real world collaboration for translational and outcomes research in precision oncology;

15:55-16:15

Giuseppe Testa, President, ACC GDPR Committee; IEO IRCCS; Milan University and Human Technopole

Making the most of GDPR: the national ACC-GDPR Commission and the contemporary research ecosystem,

16:15-17:30

Round Table

Discussants **Francesco Profumo**, Fondazione Compagnia SanPaolo
Anna Paganoni, Politecnico Milano
Salvatore Rossi, President, Telecom Italia
Andrea Di Santo, Cassa Depositi e Prestiti
Sergio Liberatore, Italy General Manager, IQVIA
Vincenzo Valentini, IRCCS Policlinico Gemelli
Filippo De Braud, INT IRCCS and University of Milan
Antonio Zoccoli, INFN
Invited speakers, Highlight Session 2

17:30-19:00

Discussion Forum: Role of Collaborative Networks in cancer research and practice.

Chairs **Ruggero De Maria**, President, Alliance Against Cancer
Giovanni Leonardi, General Director of Research and Innovation in Health

Discussants **Nicholas Jones**, Cancer Grand Challenge programme, University of Manchester
Giulio Draetta, Senior Vice President and Chief Scientific Officer, MD Anderson Cancer Center, Houston, TX
Jean-Yves Blay, President, Unicancer; General Director, Centre Léon Bérard, Lyon; Director, EURACAN
Simon Oberst, Chair, OECI Accreditation Board, and Director of Clinical Development, the CRUK Cambridge Centre
Walter Ricciardi, UE Mission Board for Cancer and Scientific Director, ICS Maugeri IRCCS

Friday

PROGRAM 30-10-2020

08:30-13:15

HIGHLIGHT SESSION 3: ACCESS OF PATIENTS TO GENOMIC SCREENS AND NEW DRUGS

Chairs **Gennaro Ciliberto**, Scientific Director, IRE and Alliance Against Cancer
Ruggero De Maria, President, Alliance Against Cancer
Pier Giuseppe Pelicci, Scientific Coordinator, Alliance Against Cancer;
Director of Research, IEO IRCCS; University of Milan

08:30-09:15

Fabien Calvo, Gustave Roussy

Genomics and Drug developments: the two revolutions in the last 20 years in cancer management and care

09:15-09:35

Vanesa Gregorc, HSR

The ACC Lung cancer trial

09:35-09:55

Domenica LoRusso, IRCCS Policlinico Gemelli

The ACC GerSom trial

09:55-10:15

Concetta Quintarelli, Bambino Gesù Hospital

CAR T program in ACC: activity framework and advances

10:15-10:35

Luca Mazarella, IEO IRCCS

The Liquid Biopsy (OncoNGS Consortium)

10:35-10:55

Giovanni Tonon, HSR Milan

One Million Genome Project

10:55-11:15

Nello Martini, Fondazione Ricerca e Salute

ACC-AIOM project on mutational oncology

11:15-11:35

Sandro Pignata, Istituto Nazionale TUMORI IRCCS Pascale (video)

Forza: the ACC clinical research infrastructure

11:35-13:15

Round Table

Discussants

Saverio Cinieri, AIOM (video)

Nicola Magrini, General Director, AIFA (*)

Giselda Scalera, Research and Innovation in Health

Paolo Marchetti, Direttore Polo Oncologico Università La Sapienza

Alberto Bardelli, Candiolo IRCCS

Invited speakers, Highlight Session 3

13:15-14:15

ACC Priorities

Chairs

Ruggero De Maria, President, Alliance Against Cancer

Paolo De Paoli, General Manager, Alliance Against Cancer

13:15-13:45

Pier Giuseppe Pelicci, Scientific Coordinator, Alliance Against Cancer;
Director, Research Area IEO IRCCS; University of Milan

13:45-14:15

Discussion

14:15-14:45

Meeting Conclusions

Ruggero De Maria, President, Alliance Against Cancer

Introduced by

Giovanni Leonardi, General Director of Research and Innovation in Health

14:45-19:45

ACC WORKSHOP

2020 Activity-report and 2021 scientific plans

Workshop Coordinators

Myriam Alcalay, IEO IRCCS

Gennaro Ciliberto, Scientific Director, IRE and Alliance Against Cancer

Ruggero De Maria, President, Alliance Against Cancer

Pier Giuseppe Pelicci, Scientific Coordinator, Alliance Against Cancer;
Director of Research, IEO IRCCS; University of Milan

(*) To be confirmed

14:45-15:05

Caterina Marchiò, IRCCS Candiolo

15:05-15:25

Luca Mazzeola, IEO IRCCS

15:25-15:45

Paola Nisticò, IRE Rome

15:45-16:05

Luca Boldrini, IRCCS Policlinico Gemelli

16:05-16:25

Giulia Buzzatti, San Martino Hospital IRCCS

16:25-16:45

Gaetano Finocchiaro, Besta IRCCS

16:45-17:05

Gian Domenico Russo, IDI IRCCS

17:05-17:25

Roberta Maestro, CRO Aviano IRCCS

17:25-17:45

Katia Scotlandi, IOR IRCCS

17:45-18:05

Enrico Derenzini, IEO IRCCS

18:05-18:25

Enzo Medico, IRCCS Candiolo

18:25-19:45

General Discussion

WG PATHOLOGY

WG GENOMICS

WG IMMUNOTHERAPY

WG RADIOMICS

WG BREAST

WG GLIOBLASTOMA

WG MELANOMA

WG SARCOMA

WG SKELETAL-MUSCLE TUMORS

WG ONCO-HEMATOLOGY

WG COLON



The largest Italian network for cancer research

allianceagainstcancer.org | alleanzacontroilcancro.it